Influenza, commonly known as flu, is an infectious disease caused by RNA viruses of the family Orthomyxoviridae. The flu viruses mostly affect the respiratory tract and can lead to severe complications like pneumonia. While vaccination remains the best strategy for flu prevention, research on effective therapeutics is crucial for timely treatment.

Neuraminidase Inhibitors
Neuraminidase inhibitors are the mainstay of influenza antiviral antiviral. By blocking the viral neuraminidase enzyme, these drugs interfere with virus replication and release from infected cells. Two widely used neuraminidase inhibitors are oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamivir is administered orally as a prodrug that is rapidly converted to the active form. Zanamivir is administered via oral inhalation to directly target lung epithelial cells. Both drugs have proven effectiveness in reducing flu symptoms if taken within 48 hours of onset. However, antiviral resistance has emerged against these drugs.

Adamantanes
Adamantanes like amantadine and rimantadine target the M2 ion channel protein of influenza A viruses to inhibit viral uncoating inside the host cell. But due to their limited effectiveness and high resistance rates today, adamantanes are no longer recommended as first-line antivirals for influenza A treatment by public health agencies. Most currently circulating influenza A viruses are resistant to adamantanes.

Broad-spectrum Antivirals
Given the limitations of existing antivirals, research is exploring new drugs with broad antiviral activity against multiple Influenza Therapeutics virus subtypes. Nitazoxanide is a thiazolide antiparasitic and antiviral drug that inhibits influenza virus maturation. Favipiravir is a viral RNA polymerase inhibitor approved in Japan for flu treatment. It has shown efficacy against various influenza subtypes as well as other RNA viruses. Other compounds in preclinical development target host factors essential for viral replication across subtypes. Such broad-spectrum antivirals hold promise due to their potential to treat emergent influenza strains.

Monoclonal Antibodies
Passive immunotherapy with monoclonal antibodies (mAbs) is a therapeutic strategy to confer rapid, short-term protection against flu. These are recombinant human or humanized mAbs that target major influenza viral proteins like hemagglutinin or neuraminidase. Some mAbs in development include lumacaftor (VX-135), VIS410, and laninamivir octanoate. While mAbs can provide immediate protection when given within 3 days of influenza onset, their high production cost and short half-life limit widespread use. Researchers are working to extend mAb half-life through engineering and formulations.

Host Modulators
Host-targeting or immunomodulatory drugs aim to enhance innate immune response against viral infection by modulating host pathways. Some host targets under investigation include protease inhibitors, cytokines, chemokines, pattern recognition receptor agonists, apoptosis inhibitors, autophagy modulators and RNA interference molecules. While host modulators might provide novel mechanisms of action with broad coverage, more research is needed to validate their antiviral activity and safety profile specifically for influenza. Combination with antivirals could yield additive benefits.

Vaccines as Therapeutics
Vaccination is the most effective strategy for preventing influenza illness and its complications. However, vaccine administration requires 2 weeks for adequate seroprotection to develop. Researchers are exploring the potential therapeutic use of inactivated or live-attenuated influenza virus (LAIV) vaccines when administered even after symptom onset. While vaccine-based therapeutics seem promising, more data from clinical studies are awaited to evaluate their safety, efficacy and potential benefits compared to antiviral treatment in hospitalized patients. Therapeutic vaccination coupled with antivirals may enhance clinical outcomes.

There has been significant progress in developing optimized therapeutics for influenza treatment. While neuraminidase inhibitors remain the predominant antivirals used worldwide, issues around resistance and efficacy demand continued research on novel targets and broad-spectrum drugs. Monoclonal antibodies, host modulators and vaccination strategies also offer hope as adjunct or alternative anti-influenza therapies. To curb the significant burden of seasonal and pandemic influenza, a diversified armamentarium with multiple treatment options is needed.

  Get More Insights on Influenza Therapeutics

Get this Report in Japanese Language- インフルエンザ治療薬

Get this Report in Korean Language-   인플루엔자 치료제

About Author-

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )